Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy. The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur. The solution is set to launch in selected European markets in the coming months. Clinical evaluations have demonstrated the new CGM solution's high system accuracy, with an o ...